Antibody News and Research

RSS
An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Further Reading

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

Roche, Bristol-Myers Squibb to evaluate YERVOY and vemurafenib treatment for metastatic melanoma

4 Jun 2011
New approach for identifying 'self' proteins targeted in autoimmune diseases

New approach for identifying 'self' proteins targeted in autoimmune diseases

3 Jun 2011
IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

IMUC, BioWa sign license deal to develop ADCC enhanced antibodies for cancer

3 Jun 2011
Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

Positive interim results from iBio's H1N1 influenza subunit vaccine Phase 1 trial

3 Jun 2011
Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

Final analysis of AVEO's tivozanib Phase 2 trial on kidney cancer patients presented at ASCO 2011

2 Jun 2011
Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial

Positive interim results from Fraunhofer USA CMB's HAC1 influenza vaccine Phase 1 trial

2 Jun 2011
AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

AVEO’s ficlatuzumab-gefitinib Phase 1b/2 trial data against NSCLC to be presented at ASCO 2011

2 Jun 2011
Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

Symphogen's rozrolimupab Phase 2 data to be presented at European Hematology Association meeting

2 Jun 2011
Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

Patients with advanced NSCLC can benefit from less toxic combination of erlotinib, bevacizumab

2 Jun 2011
Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

Preliminary results from Eisai's lenvatinib Phase II trial in thyroid cancer to be presented at ASCO 2011

1 Jun 2011
Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

Symphogen's Sym004 Phase 1 data on advanced solid tumors to be presented at ASCO 2011

1 Jun 2011
Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

1 Jun 2011
Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

1 Jun 2011
YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

31 May 2011
YM announces updates on nimotuzumab clinical development program

YM announces updates on nimotuzumab clinical development program

31 May 2011
Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

Heptares, AstraZeneca partner to discover and develop new GPCR drug targets

31 May 2011
Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

Positive data from Augurex's RA biomarker blood test, novel drug target presented at EULAR conference

30 May 2011
New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

New positive Cimzia phase IIIb study data on rheumatoid arthritis presented at EULAR meeting

30 May 2011
Transgenomic secures exclusive license from Montefiore for cancer predictive markers

Transgenomic secures exclusive license from Montefiore for cancer predictive markers

27 May 2011
4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

4SC to present pre-clinical data on vidofludimus in systemic lupus erythematosus at EULAR 2011

27 May 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback